FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4229067039> ?p ?o ?g. }

• W4229067039 endingPage "422" @default.
• W4229067039 startingPage "415" @default.
• W4229067039 abstract "Background Overexpression of the epidermal growth factor receptor (EGFR) and its ligands occur frequently in renal cell carcinoma (RCC). Combined vascular endothelial growth factor receptor (VEGF-R) and EGFR inhibition may overcome resistance to VEGF-R inhibitor monotherapy. We performed a dose-escalation phase II study of sunitinib plus erlotinib in advanced renal cell carcinoma. Patients and Methods Patients with metastatic clear cell or papillary RCC were eligible. Prior therapy was allowed except sunitinib or erlotinib. Three dose levels of erlotinib (50, 100, 150 mg daily) were evaluated in combination with sunitinib 50 mg. Thirty-seven patients were treated at maximum tolerated dose to determine efficacy. The primary endpoint was 8-month progression-free survival (PFS) rate. The trial was powered to assess for a difference between a median PFS of less than 50% with a targeted 70% PFS for the combination. Results The 8-month PFS rate was 40% (95% CI: 23-56). Median PFS was 5.8 months (95% CI: 4.1-9.7) and median overall survival (OS) was 26.3 months (95% CI: 16.1-34.0). The objective response rate was 22% and an additional 59% of patients had stable disease for at least 6 weeks. The most common adverse events for all grades were diarrhea, rash, fatigue, and dysgeusia. Dose reduction in 1 or both of the drugs was undertaken in 17 (46%) patients, while 5 (14%) discontinued study therapy due to toxicity. Conclusion While sunitinib and erlotinib are combinable,the 8-month PFS rate did not suggest efficacy improvement over sunitinib monotherapy (NCT00425386)." @default.
• W4229067039 created "2022-05-08" @default.
• W4229067039 creator A5000308328 @default.
• W4229067039 creator A5005233999 @default.
• W4229067039 creator A5029588412 @default.
• W4229067039 creator A5031088617 @default.
• W4229067039 creator A5042631007 @default.
• W4229067039 creator A5048477205 @default.
• W4229067039 creator A5050158075 @default.
• W4229067039 creator A5060004875 @default.
• W4229067039 date "2022-10-01" @default.
• W4229067039 modified "2023-10-16" @default.
• W4229067039 title "A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma" @default.
• W4229067039 cites W1880365120 @default.
• W4229067039 cites W2019607817 @default.
• W4229067039 cites W2025255125 @default.
• W4229067039 cites W2029126579 @default.
• W4229067039 cites W2088117905 @default.
• W4229067039 cites W2089964228 @default.
• W4229067039 cites W2104540972 @default.
• W4229067039 cites W2105677187 @default.
• W4229067039 cites W2105984177 @default.
• W4229067039 cites W2114157314 @default.
• W4229067039 cites W2116949558 @default.
• W4229067039 cites W2121306031 @default.
• W4229067039 cites W2129417849 @default.
• W4229067039 cites W2131473358 @default.
• W4229067039 cites W2135148499 @default.
• W4229067039 cites W2138297714 @default.
• W4229067039 cites W2143813821 @default.
• W4229067039 cites W2145816851 @default.
• W4229067039 cites W2149456801 @default.
• W4229067039 cites W2151856174 @default.
• W4229067039 cites W2159870435 @default.
• W4229067039 cites W2754665605 @default.
• W4229067039 cites W2792937256 @default.
• W4229067039 cites W2794354720 @default.
• W4229067039 cites W2913745075 @default.
• W4229067039 cites W2963695239 @default.
• W4229067039 cites W2993418536 @default.
• W4229067039 cites W4244590756 @default.
• W4229067039 doi "https://doi.org/10.1016/j.clgc.2022.04.018" @default.
• W4229067039 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35688679" @default.
• W4229067039 hasPublicationYear "2022" @default.
• W4229067039 type Work @default.
• W4229067039 citedByCount "0" @default.
• W4229067039 crossrefType "journal-article" @default.
• W4229067039 hasAuthorship W4229067039A5000308328 @default.
• W4229067039 hasAuthorship W4229067039A5005233999 @default.
• W4229067039 hasAuthorship W4229067039A5029588412 @default.
• W4229067039 hasAuthorship W4229067039A5031088617 @default.
• W4229067039 hasAuthorship W4229067039A5042631007 @default.
• W4229067039 hasAuthorship W4229067039A5048477205 @default.
• W4229067039 hasAuthorship W4229067039A5050158075 @default.
• W4229067039 hasAuthorship W4229067039A5060004875 @default.
• W4229067039 hasConcept C121608353 @default.
• W4229067039 hasConcept C126322002 @default.
• W4229067039 hasConcept C126894567 @default.
• W4229067039 hasConcept C143998085 @default.
• W4229067039 hasConcept C197934379 @default.
• W4229067039 hasConcept C203092338 @default.
• W4229067039 hasConcept C2776694085 @default.
• W4229067039 hasConcept C2777054765 @default.
• W4229067039 hasConcept C2777472916 @default.
• W4229067039 hasConcept C2778087573 @default.
• W4229067039 hasConcept C2778570526 @default.
• W4229067039 hasConcept C2779438470 @default.
• W4229067039 hasConcept C2779490328 @default.
• W4229067039 hasConcept C2780739268 @default.
• W4229067039 hasConcept C29730261 @default.
• W4229067039 hasConcept C31760486 @default.
• W4229067039 hasConcept C535046627 @default.
• W4229067039 hasConcept C71924100 @default.
• W4229067039 hasConcept C90924648 @default.
• W4229067039 hasConceptScore W4229067039C121608353 @default.
• W4229067039 hasConceptScore W4229067039C126322002 @default.
• W4229067039 hasConceptScore W4229067039C126894567 @default.
• W4229067039 hasConceptScore W4229067039C143998085 @default.
• W4229067039 hasConceptScore W4229067039C197934379 @default.
• W4229067039 hasConceptScore W4229067039C203092338 @default.
• W4229067039 hasConceptScore W4229067039C2776694085 @default.
• W4229067039 hasConceptScore W4229067039C2777054765 @default.
• W4229067039 hasConceptScore W4229067039C2777472916 @default.
• W4229067039 hasConceptScore W4229067039C2778087573 @default.
• W4229067039 hasConceptScore W4229067039C2778570526 @default.
• W4229067039 hasConceptScore W4229067039C2779438470 @default.
• W4229067039 hasConceptScore W4229067039C2779490328 @default.
• W4229067039 hasConceptScore W4229067039C2780739268 @default.
• W4229067039 hasConceptScore W4229067039C29730261 @default.
• W4229067039 hasConceptScore W4229067039C31760486 @default.
• W4229067039 hasConceptScore W4229067039C535046627 @default.
• W4229067039 hasConceptScore W4229067039C71924100 @default.
• W4229067039 hasConceptScore W4229067039C90924648 @default.
• W4229067039 hasFunder F4320307769 @default.
• W4229067039 hasFunder F4320332759 @default.
• W4229067039 hasIssue "5" @default.
• W4229067039 hasLocation W42290670391 @default.
• W4229067039 hasLocation W42290670392 @default.

• next